All News

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, have been consistently inconsistent.

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

After a diagnosis of stage 3 breast cancer at age 32, Moana Papa embraced advocacy, traveling from her home in New Zealand to the San Antonio Breast Cancer Symposium to bring information back to her community.

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype.

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results.

After breast cancer, clinical sexologist Sueann Mark, PhD, developed a program to help survivors regain their sexuality after cancer.

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials.

Two studies presented at SABCS offer a better understanding of what to do with the information sentinel lymph nodes provide.

When faced with breast cancer as a young Jewish woman, Rochelle Shoretz learned that her heritage, including its risk of cancer-associated mutations, brought up unique issues, which led her to create Sharsheret, a nonprofit organization.

Findings from the long-awaited AZURE trial show Zometa may prevent recurrence, but not for everyone.

Not only is weight training safe, but for women who have had lymph node removal due to breast cancer surgery, it also may reduce the risk of lymphedema by about a third.

Wanda Brown, 54, is celebrating six years of survivorship this month, and her knowledge of the disease is a far cry from that day back in 2004 when she found the lump in her breast.

A recap of the 2008 San Antonio Breast Cancer Symposium.

Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said Susan Domchek, MD, one of the educational sessions speakers at the 2010 SABCS.

News of Elizabeth Edwards' death heightens a sense of urgency at the 33rd annual San Antonio Breast Cancer Symposium among patients, survivors and advocates.